| Folic acid | cardiovascular prevention, in all type of patients | vs control | Non fatal MI by 17% suggested | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| cardiovascular events | 1.10 [0.97 1.25] | p=1.00 | 0 | 6222 | 3 | NORVIT (folic acid + B12) (Bonaa), NORVIT (folic acid, B12 and vit B6) (Bonaa), GOES (Liem), | | Cardiovascular death | 0.76 [0.28 2.07] | p=1.00 | 0 | 593 | 1 | GOES (Liem), | | stroke (fatal and non fatal) | 0.95 [0.69 1.31] | p=1.00 | 0 | 6505 | 4 | NORVIT (folic acid + B12) (Bonaa), NORVIT (folic acid, B12 and vit B6) (Bonaa), FOLARDA (Liem), GOES (Liem), | | cardiac death | 1.03 [0.83 1.27] | p=1.00 | 0 | 5629 | 2 | NORVIT (folic acid + B12) (Bonaa), NORVIT (folic acid, B12 and vit B6) (Bonaa), | | Death from cancer | no data | | Non fatal MI | 1.17 [1.03 1.33] | p=0.04 | 0 | 8978 | 6 | NORVIT (folic acid + B12) (Bonaa), NORVIT (folic acid, B12 and vit B6) (Bonaa), NORVIT (folic acid, B12 and vit B6) (Bonaa), FOLARDA (Liem), GOES (Liem), GOES (Liem), | | Cancer | 1.14 [0.87 1.49] | p=1.00 | 0 | 5629 | 2 | NORVIT (folic acid + B12) (Bonaa), NORVIT (folic acid, B12 and vit B6) (Bonaa), | | All cause death | 1.05 [0.89 1.25] | p=1.00 | 0 | 6505 | 4 | NORVIT (folic acid + B12) (Bonaa), NORVIT (folic acid, B12 and vit B6) (Bonaa), FOLARDA (Liem), GOES (Liem), |
| Trial | Studied treatment | Control | Patients |
|---|
| NORVIT (folic acid + B12) (Bonaa), 2006 | folic acid 0.8mg and B12 0.4 mg daily
| no folic acid and B12
| men and women who had had an acute myocardial infarction within seven days before
| | NORVIT (folic acid, B12 and vit B6) (Bonaa), 2006 | 0.8 mg of folic acid, 0.4 mg of vitamin B12, and 40 mg of vitamin B6 | placebo | men and women who had had an acute myocardial infarction within seven days | | FOLARDA (Liem), 2004 | folic acid 5 mg per day for 1 year | usual care | patients with acute MI and total cholesterol >6.5 mmol/l | | GOES (Liem), 2003 | folic acid 0.5 mg per day | usual care | patients with stable coronary artery disease |
| |
| Folic acid | | vs placebo | stroke (fatal and non fatal) by 12% suggested | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| cardiovascular events | 0.97 [0.92 1.02] | p=1.00 | 0 | 55947 | 7 | SEARCH, WAFACS, HOPE-2 (Lonn), WENBIT (folic ac,B12), VITATOPS, CSPPT, SU.FOL.OM3, | | Cardiovascular death | 1.01 [0.93 1.11] | p=1.00 | 0 | 43730 | 4 | SEARCH, WAFACS, HOPE-2 (Lonn), CSPPT, | | stroke (fatal and non fatal) | 0.88 [0.80 0.97] | p=0.04 | 0 | 47783 | 6 | SEARCH, WAFACS, HOPE-2 (Lonn), WENBIT (folic ac,B12), CSPPT, SU.FOL.OM3, | | cardiac death | 1.06 [0.95 1.18] | p=1.00 | 0 | 17506 | 2 | SEARCH, WAFACS, | | Death from cancer | 0.99 [0.74 1.33] | p=1.00 | 0 | 5522 | 1 | HOPE-2 (Lonn), | | Non fatal MI | 1.03 [0.97 1.09] | p=1.00 | 0 | 64230 | 9 | SEARCH, SEARCH, WAFACS, HOPE-2 (Lonn), CHAOS-2, WENBIT (folic ac,B12), CSPPT, SU.FOL.OM3, SU.FOL.OM3, | | Cancer | 1.07 [0.98 1.17] | p=1.00 | 0 | 19138 | 3 | SEARCH, HOPE-2 (Lonn), WENBIT (folic ac,B12), | | All cause death | 1.02 [0.95 1.09] | p=1.00 | 0 | 47783 | 6 | SEARCH, WAFACS, HOPE-2 (Lonn), WENBIT (folic ac,B12), CSPPT, SU.FOL.OM3, |
| Trial | Studied treatment | Control | Patients |
|---|
| SEARCH, 2007 | folic acid 2mg/d + vitamin B12 1mg/d | placebo | patients survivors of myocardial infarction | | WAFACS, 2008 | folic acid 2.5mg, vitamin B6 50mg, and vitamin B12 1mg daily | placebo | women aged 42 years or older, with either a history of CVD or 3 or more coronary risk factors | | HOPE-2 (Lonn), 2006 | folic acid, 2.5 mg, vitamin B6,50 mg and vitamin B12, 1mg | placebo | patients 55 years of age or older who had vascular disease
or diabetes and
additional risk factors for atherosclerosis | | CHAOS-2, 2002 | folic acid 5 mg per day (for 2 years) | placebo | patient with CHD | | WENBIT (folic ac,B12), 2008 | folic acid 0.8mg, vit B12 0.4mg daily
| placebo
| adult participants undergoing coronary angiography
| | VITATOPS, 2010 | folic acid and vitamins B12 and B6 in a single tablet | placebo | patients with recent stroke or TIA (within the past seven months) | | CSPPT, 2015 | enalapril 10 mg / folic acid 0.8 mg daily | Enalapril maleate 10 mg daily | patients with primary hypertension | | SU.FOL.OM3, | supplementation with natural foLate, vitamin B6 and B12 | placebo | patients with coronary or cerebral event within the previous 12 months |
| |
| Folic acid | | vs low dose - folic acid, vit B12 and vit B6 | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| cardiovascular events | 0.97 [0.82 1.16] | p=1.00 | 0 | 3680 | 1 | VISP (Toole), | | Cardiovascular death | no data | | stroke (fatal and non fatal) | 1.04 [0.82 1.32] | p=1.00 | 0 | 3680 | 1 | VISP (Toole), | | cardiac death | no data | | Death from cancer | no data | | Non fatal MI | 0.90 [0.65 1.25] | p=1.00 | 0 | 3680 | 1 | VISP (Toole), | | Cancer | no data | | All cause death | 0.86 [0.65 1.13] | p=1.00 | 0 | 3680 | 1 | VISP (Toole), |
| Trial | Studied treatment | Control | Patients |
|---|
| VISP (Toole), 2004 | high-dose of folic acid, pyridoxine (vitamin B6),
and cobalamin (vitamin B12) | low-dose of folic acid, pyridoxine (vitamin B6),
and cobalamin (vitamin B12) | adults with nondisabling cerebral infarction |
| |
